Last $12.87 USD
Change Today +0.04 / 0.31%
Volume 595.6K
DEPO On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

depomed inc (DEPO) Snapshot

Open
$12.80
Previous Close
$12.83
Day High
$13.18
Day Low
$12.56
52 Week High
03/13/14 - $15.39
52 Week Low
05/10/13 - $4.99
Market Cap
743.7M
Average Volume 10 Days
1.3M
EPS TTM
$0.74
Shares Outstanding
57.8M
EX-Date
--
P/E TM
17.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for DEPOMED INC (DEPO)

depomed inc (DEPO) Related Businessweek News

No Related Businessweek News Found

depomed inc (DEPO) Details

Depomed, Inc., a specialty pharmaceutical company, develops products for pain and other conditions, and diseases of the central nervous system in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Lazanda (fentanyl) Nasal Spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company is also involved in the clinical development of DM-1992 that completed a Phase II trial for Parkinson's disease. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. It has license and collaboration agreements with Abbott Products Inc.; Santarus, Inc.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Janssen Pharmaceutica N.V.; Janssen Pharmaceuticals, Inc.; Mallinckrodt; Patheon Puerto Rico, Inc.; and Valeant Pharmaceuticals International, Inc. The company was founded in 1995 and is headquartered in Newark, California.

291 Employees
Last Reported Date: 03/17/14
Founded in 1995

depomed inc (DEPO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $590.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $363.9K
Senior Vice President and General Counsel
Total Annual Compensation: $380.0K
Senior Vice President of Business Development
Total Annual Compensation: $327.8K
Compensation as of Fiscal Year 2013.

depomed inc (DEPO) Key Developments

Cadila Healthcare and Zydus Pharmaceuticals (USA), Inc. Enter into Settlement Agreement with Depomed on Gralise

Cadila Healthcare and Zydus Pharmaceuticals (USA) Inc. have entered into a settlement agreement with Depomed Inc. to settle their ongoing patent infringement litigation related to Gralise (gabapentin) 300 mg and 600 mg tablets. The settlement permits Cadila and Zydus to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The agreement is subject to review by the US Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the US District Court for the District of New Jersey.

DepoMed Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for Year Ending December 31, 2014

DepoMed Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenues of $40,609,000 against $26,590,000 a year ago. Income from operations was $7,480,000 against loss from operations of $3,891,000 a year ago. Net income was $41,801,000 or $0.72 per diluted share against net loss of $3,704,000 or $0.07 per diluted share a year ago. For the full year, the company reported total revenues of $134,205,000 against $90,816,000 a year ago. Income from operations was $9,317,000 against loss from operations of $30,353,000 a year ago. Net income was $43,313,000 or $0.75 per diluted share against net loss of $29,781,000 or $0.53 per diluted share a year ago. Net income before taxes was $4.6 million. For the year 2014, the company expects product sales of approximately $115 to $125 million; total revenues of approximately $200 to $215 million, which includes non-cash revenues related to the PDL transaction and $15 million in potential milestones from Mallinckrodt; GAAP earnings per share of approximately $0.21 to $0.36 per share, which includes the non-cash PDL revenues and non-cash PDL interest expense; Non-GAAP adjusted earnings per share of break-even to $0.16 per share; cash flow of at least break-even excluding payment of approximately $59 million in taxes in the first quarter of 2014 related to fiscal year 2013.

DepoMed Inc., Q4 2013 Earnings Call, Mar 12, 2014

DepoMed Inc., Q4 2013 Earnings Call, Mar 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DEPO:US $12.87 USD +0.04

DEPO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $7.42 USD +0.02
Horizon Pharma Inc $13.37 USD +0.19
Insys Therapeutics Inc $38.64 USD +1.88
Nektar Therapeutics $10.97 USD -0.075
Skyepharma PLC 223.00 GBp +14.00
View Industry Companies
 

Industry Analysis

DEPO

Industry Average

Valuation DEPO Industry Range
Price/Earnings 17.1x
Price/Sales 5.5x
Price/Book 5.4x
Price/Cash Flow 15.5x
TEV/Sales 3.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEPOMED INC, please visit www.depomedinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.